Intermediate Uveitis: Outlook Good but Course Long


Patients with intermediate uveitis (IU) have a high likelihood of achieving good long-term visual outcomes, but should expect a long disease course and frequent complications

Patients with intermediate uveitis (IU) have a high likelihood of achieving good long-term visual outcomes, but should expect a long disease course and frequent complications, according to a study presented at the annual meeting of the American Academy of Ophthalmology in Chicago, IL, in October 2016. Oren Tomkins-Netzer, MD, of the Moorfields Eye Hospital in London, UK, presented the findings in a poster session.

The researchers begin by saying, “Intermediate uveitis is a relatively common occurrence among uveitis patients, and is reported to constitute 2-31% of subjects seen in tertiary uveitis clinics.” They add that sarcoidosis and multiple sclerosis are the most frequently reported systemic associations in IU, and “cataract and cystoid macular edema (CME) are the most common complications, and incidence increases with duration of follow-up.”

“This study aimed to examine a large population of subjects with IU with a long follow up period, to determine clinical outcome, systemic associations, treatment, complications and risk factors for visual loss,” state the researchers. In order to investigate, they conducted a retrospective study that included all of the patients seen for IU by a single consultant at Moorfields Eye Hospital in London between 2011 and 2013.

There were 305 patients in total, and the median follow up was 8.2 years. Raised intraocular pressure, glaucomatous optic neuropathy, cataract, cystoid macular edema, epiretinal membrane, macular scarring, retinal detachment, and hypotony and phthisis were all complications seen among them. Although the majority of the patients suffered complications over a long course of time, most had good visual outcomes.

The researchers conclude with two findings. First, they say, “The disease course of IU is long and subjects frequently experience multiple complications of both the disease and the treatment.” Second, “careful management results in most subjects achieving good visual outcomes, and permanent visual loss is uncommon,” the researchers say.

Related Coverage:

Central Foveal Thickness Cut-off Value Identitfied for Corticosteroid Treatment in Intermediate Uveitis

Study Shows TNF Inhibitors Prevent Relapse of Uveitis in Most Patients with Ankylosing Spondylitis

Assessing Rates of Noninfectious Vitritis after Intravitreal Injection of Anti-VEGF Agents

Related Videos
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.